T-helper type 2 cytokines (Th2 cytokines)

T-helper type 2 (Th2) cytokines are a group of signaling proteins primarily produced by Th2 cells, including Interleukin-4 (IL-4), Interleukin-5 (IL-5), and Interleukin-13 (IL-13). These cytokines play a central role in coordinating the type 2 immune response, which is essential for host defense against extracellular parasites like helminths but is also the primary driver of allergic diseases (NIH, 2023). IL-4 and IL-13 are critical for B-cell isotype switching to IgE and airway hyperresponsiveness, while IL-5 is the principal cytokine responsible for the maturation, recruitment, and survival of eosinophils (StatPearls, 2023). In clinical practice, Th2 cytokines are major therapeutic targets for chronic inflammatory conditions such as moderate-to-severe asthma and atopic dermatitis. Biologic therapies, such as Dupilumab (targeting the IL-4Rα subunit shared by IL-4 and IL-13) and Mepolizumab (targeting IL-5), have revolutionized the treatment of 'Type 2-high' endotypes by significantly reducing exacerbation rates and improving lung function or skin barrier integrity (PubMed, 2021). Because this term refers to a heterogeneous group of proteins rather than a single molecular target, drug development is typically focused on neutralizing specific cytokines or their individual receptors within this pathway.

Other names

Type 2 cytokinesTh2-related interleukinsTh2 cell-derived cytokines

Monoclonal antibodies that either bind directly to the Th2 cytokines (such as IL-5, IL-13) or their shared receptor subunits (such as IL-4Rα, IL-5Rα) to block downstream signaling through the JAK-STAT pathway, thereby reducing allergic inflammation and tissue remodeling.